- $196.39m
- $200.62m
- $52.84m
Apyx Medical falls on FDA warning on use of device for aesthetic procedures
Brief: FDA Says Received Reports Describing Serious Adverse Events When Renuvion/J-Plasma Device Was Used Directly On Skin
Brief: Apyx Medical Notified Of Pending FDA Medical Device Safety Communication Related To Advanced Energy Products
Brief: Apyx Medical Corporation Announces Peer-Reviewed Publication Featuring Results From Study Of The Renuvion® Dermal Handpiece
Brief: Apyx Medical Corporation Reports Preliminary Fourth Quarter And Full Year 2021 Revenue Results
U.S. RESEARCH ROUNDUP-Acutus Medical, Lordstown Motors, Walmart
Apyx Medical Corp reports results for the quarter ended in September - Earnings Summary
Brief: Apyx Medical Corporation Reports Third Quarter 2021 Financial Results And Updates Full Year 2021 Outlook
Apyx Medical Corp expected to post a loss of 15 cents a share - Earnings Preview
NASDAQ RESUMED AT 01:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:19 PM
Brief: Apyx Medical Corporation Announces Appointment Of Wendy Levine To The Company’S Board Of Directors
U.S. RESEARCH ROUNDUP- Abcellera Biologics, Linde, Spire
Apyx Medical up on upbeat forecast
Apyx Medical Corp reports results for the quarter ended in June - Earnings Summary
Brief: Apyx Medical Corporation Reports Second Quarter 2021 Financial Results And Updates Full Year 2021 Outlook
BiVictriX Therapcts. - Admission to Trading on AIM & First Day Dealings
Apyx Medical Corp expected to post a loss of 15 cents a share - Earnings Preview
Brief: Apyx Medical Corporation Announces FDA 510(K) Submission For The Use Of Renuvion® In Dermal Resurfacing Procedures